Want to see COR full AI Analyst Report?
COR Stock Chart & Stats
$311.15
$1.26(0.41%)
At close: 4:00 PM EDT
$311.15
$1.26(0.41%)
Day’s Range― - ―
52-Week Range$244.82 - $377.54
Previous Close$311.15
Volume1.00M
Average Volume (3M)1.53M
Market Cap
$60.69B
Enterprise Value$63.93K
Total Cash (Recent Filing)$2.82B
Total Debt (Recent Filing)$11.72B
Price to Earnings (P/E)23.5
Beta0.11
Next Earnings
Nov 11, 2026EPS Estimate
4.56Next Dividend Ex-DateN/A
Dividend Yield0.75%
Share Statistics
EPS (TTM)13.52
Shares Outstanding190,827,160
10 Day Avg. Volume1,332,233
30 Day Avg. Volume1,526,423
Financial Highlights & Ratios
PEG Ratio7.05
Price to Book (P/B)40.17
Price to Sales (P/S)0.19
P/FCF Ratio18.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$369.18Price Target Upside18.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)17.87
Revenue Forecast (FY)$337.23B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationCencora’s substantial cash generation supports ongoing investment, debt repayment and shareholder returns. Although conversion varies with working capital, the absolute cash flow provides durable financial flexibility for a distribution business.
Specialty Healthcare GrowthSpecialty pharmaceuticals and GLP-1 therapies are structurally expanding areas of healthcare demand. Cencora’s distribution and provider-service capabilities position it to capture higher-growth volumes and broaden its role in complex therapies.
Operating Profit MomentumOperating income growth above revenue growth indicates improving execution and mix, particularly from specialty activities and international operations. The raised guidance also suggests management sees these profitability drivers as sustainable beyond one quarter.
Bears Say
Elevated Financial LeverageHigh leverage and historically weak equity reduce balance-sheet resilience and increase sensitivity to working-capital swings, interest costs and acquisition integration. Debt repayment is improving flexibility, but leverage remains an above-average structural risk.
Structurally Thin MarginsPharmaceutical distribution operates on narrow spreads, leaving limited protection if pricing, volumes or contract economics weaken. Even with improved operating profitability, Cencora’s earnings remain more sensitive to small margin changes than those of higher-margin healthcare businesses.
Pricing And Customer Concentration PressureLarge manufacturer price reductions and customer-specific volume changes can pressure reported growth and distribution economics. The core Walgreens agreement remains intact, but these events highlight continuing exposure to concentrated contracts and supplier pricing decisions.
Cencora News
COR FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was $244.82 and its highest was $377.54 in the past 12 months.
What is Cencora’s market cap?
Cencora’s market cap is $60.69B.
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Nov 11, 2026 which is in 79 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Aug 05, 2026. The company reported $4.48 earnings per share for the quarter, beating the consensus estimate of $4.347 by $0.133.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.75%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is 4.56.
How many shares outstanding does Cencora have?
Cencora has 190,827,160 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $4.48 in its last earnings report, beating expectations of $4.347. Following the earnings report the stock price went up 3.572%.
Which hedge fund is a major shareholder of Cencora?
Currently, no hedge funds are holding shares in COR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$369.18 (18.65% Upside)
$369.18 (18.65% Upside)
Blogger Sentiment
Bullish
COR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 21.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.49%
12-Months-Change
Fundamentals
Return on Equity
0.75%
Trailing 12-Months
Asset Growth
14.69%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
COR Company Deck
COR Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong execution and durable specialty-driven growth: consolidated revenue and adjusted gross profit growth, margin expansion, double-digit operating income increases, 12% EPS growth, upgraded EPS guidance, significant share repurchases, and robust free cash flow. Key drivers included strong U.S. Healthcare Solutions performance (MSOs and specialty), International momentum, and OneOncology outperforming expectations. Headwinds discussed were notable but largely manageable: $2.4B of manufacturer list-price reductions, a prior oncology customer loss, lower mail-order sales, acquisition-related higher operating expenses and increased interest expense, and a potential FY27 earnings headwind from the planned MWI transaction. Overall, the positive operational and financial outcomes and guidance raise outweigh the discrete and partly acquisition-related challenges.View all COR earnings summariesCOR Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations
COR Stock 12 Month Forecast
Average Price Target
$369.18
▲(18.65% Upside)
Technical Analysis
Cardinal Health
―
Henry Schein
―
McKesson
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
0.36% Insiders
31.40% Mutual Funds
16.25% Other Institutional Investors
23.99% Public Companies and
Individual Investors